Abstract: Disclosed are a composition and method for the diagnosis of diseases accompanied by impaired glucose tolerance, comprising a material for ITIH1 detection. The composition and method according to the present application enable a relatively sensitive response even to small changes in blood sugar according to various stimulants in a hyperglycemic situation as compared to glycated hemoglobin (HbA1c) which is an existing diagnostic marker widely used for patients with diabetes, which is a typical disease accompanied by impaired glucose tolerance, and thus can more precisely detect blood sugar changes under various stress situations.

Abstract: A pharmaceutical composition for improving insulin sensitivity in diseases accompanied by impaired glucose tolerance is disclosed. The pharmaceutical composition contains an antibody or an antigen-binding fragment thereof that specifically recognizes ITIH1 exhibiting increased expression in diseases accompanying high blood sugar. The pharmaceutical composition can be effectively used for improving insulin sensitivity in various diseases accompanying high blood sugar.

Abstract: The present invention relates to human Her-2/neu expressing plasmid constructs having anti-cancer activity and a DNA vaccine comprising same for preventing and/or treating cancer. The Her-2/neu DNA vaccines of the present invention can be effectively used as a therapeutic vaccine in reducing metastasis after tumor surgery or as a prophylactic vaccine for people with genetic high risk.

Abstract: The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with ?-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor.

Abstract: The present invention relates to human Her-2/neu expressing plasmid constructs having anti-cancer activity and a DNA vaccine comprising same for preventing and/or treating cancer. The Her-2/neu DNA vaccines of the present invention can be effectively used as a therapeutic vaccine in reducing metastasis after tumor surgery or as a prophylactic vaccine for people with genetic high risk.

Abstract: The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with ?-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor.

Abstract: The present invention relates to human Her-2/neu expressing plasmid constructs having anti-cancer activity and a DNA vaccine comprising same for preventing and/or treating cancer. The Her-2/neu DNA vaccines of the present invention can be effectively used as a therapeutic vaccine in reducing metastasis after tumor surgery or as a prophylactic vaccine for people with genetic high risk.